PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS

Abstract: pharmacoeconomic study of treatment primary open-angle glaucoma with fix combination of carbonic anhydrise inhibitors and betablockers by mean of cost-utility, willingness-to-pay, cost minimization and budget impact analysis was conducted. Results have shown, that Azarga has benefits compa...

Full description

Bibliographic Details
Main Author:	M. V. Protsenko
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2015-03-01
Series:	Фармакоэкономика
Subjects:	primary open-angle glaucoma pharmacoeconomic studies cost-utility analysis willingness-to-pay analysis cost minimization analysis budget impact analysis timolol brinzolamid
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/38

Similar Items

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

Comparative study to assess efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in management of open-angle glaucoma
by: Prerana Agarwal, et al.
Published: (2022-01-01)

Pharmacoeconomic research of surgical treatment of juvenile nasopharyngeal angiofibroma: preoperative endovascularly occlusion classes
by: I. V. Zyabkin, et al.
Published: (2020-10-01)

Pharmacoeconomic research of surgical treatment of juvenile nasopharyngeal angiofibroma: preoperative endovascularly occlusion classes
by: I. V. Zyabkin, et al.
Published: (2022-07-01)

On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers
by: Andrea Carta, et al.
Published: (2020-10-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2022-12-01)

Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: A hospital-based, prospective, randomized study
by: Mary S Galose, et al.
Published: (2016-01-01)

Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
by: Hui-Yao Huang, et al.
Published: (2020-11-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

Effect of 1% brinzolamide and 0.5% timolol fixed combination on intraocular pressure after cataract surgery with phacoemulsification
by: Kemal Örnek, et al.
Published: (2013-12-01)

Intraocular pressure-lowering effects of commonly used fixed combination drugs with timolol in the management of primary open angle glaucoma
by: Murat Atabey Ozer, et al.
Published: (2014-10-01)

METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Meta-analysis of efficacy between Travoprost and Timolol in treating primary open angle glaucoma
by: Wan-Jing Xu, et al.
Published: (2022-04-01)

Apraclonidine versus brinzolamide-timolol combination to prevent intraocular pressure elevation after laser capsulotomy
by: Erkan Çelik, et al.
Published: (2016-01-01)

PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients
by: Hiromitsu Onoe, et al.
Published: (2022-12-01)

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS
by: M. Yu. Frolov, et al.
Published: (2017-05-01)

Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia
by: Sergey V. Nedogoda, et al.
Published: (2021-12-01)

COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS
by: M. B. Kubaeva, et al.
Published: (2017-08-01)

Pharmacoeconomic analysis of naftidrofuryl for treatment of ischemic stroke
by: A. E. Cheberda, et al.
Published: (2018-05-01)

The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
by: Hiromitsu Onoe, et al.
Published: (2021-11-01)

Pharmacoeconomics of Bronchial Asthma
by: Ivanova Zlatina I., et al.
Published: (2019-06-01)

PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of cost-benefit in evaluating the effectiveness of treatment for epilepsy in adults
by: P. N. Vlasov, et al.
Published: (2010-06-01)

RETRACTED: Opportunities of the method «Budget impact analysis» for performing pharmacoeconomic research
by: V. V. Ryazhenov, et al.
Published: (2022-06-01)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
by: Lerner SF, et al.
Published: (2019-12-01)

Pharmacoeconomics of chronic kidney disease
by: R. I. Yagudina, et al.
Published: (2018-02-01)

PHARMACOECONOMIC EFFECTIVENESS OF NAFTIDROFURYL IN PATIENTS WITH ISCHEMIC STROKE
by: A. N. Bogolepova, et al.
Published: (2017-07-01)

COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus
by: A. G. Tolkushin, et al.
Published: (2018-11-01)

Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension:a systematic review and meta-analysis
by: Yi Xing, et al.
Published: (2014-10-01)

Pharmacoeconomic analysis of the use of actovegin in patients with post-stroke cognitive impairment in the health care system of the Russian Federation
by: V. V. Ryazhenov, et al.
Published: (2018-11-01)

Pharmacoeconomic analysis of Cocarnit® complex as treatment for diabetic polyneuropathy
by: D. Yu. Belousov, et al.
Published: (2018-05-01)

Papillomacular retinoschisis associated with glaucoma: Response to topical carbonic anhydrase inhibitor
by: Masatoshi Haruta, et al.
Published: (2020-09-01)

Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
by: R. I. Yagudina, et al.
Published: (2015-03-01)